126 related articles for article (PubMed ID: 35404193)
21. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
22. Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
Torre M; Vasudevaraja V; Serrano J; DeLorenzo M; Malinowski S; Blandin AF; Pages M; Ligon AH; Dong F; Meredith DM; Nasrallah MP; Horbinski C; Dahiya S; Ligon KL; Santi M; Ramkissoon SH; Filbin MG; Snuderl M; Alexandrescu S
Acta Neuropathol Commun; 2020 Jul; 8(1):107. PubMed ID: 32665022
[TBL] [Abstract][Full Text] [Related]
23. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis.
Ferris SP; Velazquez Vega J; Aboian M; Lee JC; Van Ziffle J; Onodera C; Grenert JP; Saunders T; Chen YY; Banerjee A; Kline CN; Gupta N; Raffel C; Samuel D; Ruiz-Diaz I; Magaki S; Wilson D; Neltner J; Al-Hajri Z; Phillips JJ; Pekmezci M; Bollen AW; Tihan T; Schniederjan M; Cha S; Perry A; Solomon DA
Brain Pathol; 2020 Jan; 30(1):46-62. PubMed ID: 31104347
[TBL] [Abstract][Full Text] [Related]
24. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
25. Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
Papusha L; Zaytseva M; Panferova A; Druy A; Valiakhmetova A; Artemov A; Salnikova E; Kislyakov A; Imyanitov E; Karachunsky A; Maschan A; Hwang EI; Novichkova G; Packer RJ
Neuro Oncol; 2022 Jun; 24(6):1029-1031. PubMed ID: 35196386
[No Abstract] [Full Text] [Related]
26. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
27. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
28. External Validation of
Kim SW; DO SI; Na K
Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
30. Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern.
Kao YC; Suurmeijer AJH; Argani P; Dickson BC; Zhang L; Sung YS; Agaram NP; Fletcher CDM; Antonescu CR
Genes Chromosomes Cancer; 2020 Oct; 59(10):575-583. PubMed ID: 32506523
[TBL] [Abstract][Full Text] [Related]
31. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.
Agaram NP; Zhang L; Sung YS; Chen CL; Chung CT; Antonescu CR; Fletcher CD
Am J Surg Pathol; 2016 Oct; 40(10):1407-16. PubMed ID: 27259011
[TBL] [Abstract][Full Text] [Related]
32. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
33. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
34. A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib.
Buckner-Wolfson E; Jung G; Kim T; Fatemi R; Liriano G; Dalvi N; Behbahani M; Chin S; Martin A; Kobets A
Pediatr Neurosurg; 2024; 59(1):27-34. PubMed ID: 38109857
[TBL] [Abstract][Full Text] [Related]
35. Spitz Tumors With ROS1 Fusions: A Clinicopathological Study of 6 Cases, Including FISH for Chromosomal Copy Number Alterations and Mutation Analysis Using Next-Generation Sequencing.
Donati M; Kastnerova L; Martinek P; Grossmann P; Sticová E; Hadravský L; Torday T; Kyclova J; Michal M; Kazakov DV
Am J Dermatopathol; 2020 Feb; 42(2):92-102. PubMed ID: 31361613
[TBL] [Abstract][Full Text] [Related]
36. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
37. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
38. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
39. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
40. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]